Scheduling apheresis, manufacturing the cells, and ultimately administering the treatment can take several weeks, Madhav Seshadri, MD, explains.
Madhav Seshadri, MD
Advertisement
Madhav Seshadri, MD, is an assistant professor in the malignant hematology group at UCSF, specializing in lymphoma and chronic lymphocytic leukemia.
Articles by Madhav Seshadri, MD
CAR T remains Madhav Seshadri, MD's top pick for eligible relapsed/refractory DLBCL, though bispecific antibody regimens are viable alternatives.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
3
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
4
J&J Oncology Care Index Finds Community Innovation Adoption Gap
5